In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease ...
(RTTNews) - Monte Rosa Therapeutics, Inc. (GLUE) today will present updated interim results from its ongoing Phase 1/2 study of MRT-2359 in patients with metastatic castration-resistant prostate ...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results